. 2021 Jul 7;13:11795735211029114. doi: 10.1177/11795735211029114

Table 2.

Salivary HO-1 levels (adjusted by age, sex, total protein, and comorbidities).

Primary analysis groups	n	Unadjusted analysis			Adjusted by age, sex, and comorbidities
Primary analysis groups	n	Mean (ng/ml)	95% CI	P value	Mean (ng/ml)	95% CI	P value
Non-neurological controls	162	55.79	52.17−59.41	.02	55.13	48.75−61.51	.03
Degenerative neurological controls	37	65.69	58.12−73.26	.65	60.93	51.25−70.62	.63
Non-degenerative neurological controls	33	50.55	42.53−58.56	<.01	51.61	42.19−61.03	.03
PD (reference)	75	63.56	58.24−68.88		63.40	55.75−71.05
Secondary analysis groups	n	Mean (ng/ml)	95% CI	P value	Mean (ng/ml)	95% CI	P value
Non-neurodegenerative controls (reference)	195	54.90	51.61−58.20	<.01	54.39	46.27−60.51	.02
Neurodegenerative conditions	112	64.26	59.92−68.61		62.46	55.56−69.37

ANCOVA adjustments by total protein (P_primary = .02; P_secondary = .02), age (P_primary = .08; P_secondary = .08), sex (P_primary = .51; P_secondary = .61), presence for arthritis (P_primary = .68; P_secondary = .72), diabetes (P_primary = .73; P_secondary = .69), thyroid (P_primary = .09; P_secondary = .09), and heart conditions (P_primary = .24; P_secondary = .27).